

# Kevin Kalinsky

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3153520/publications.pdf>

Version: 2024-02-01

107  
papers

2,563  
citations

218677

26  
h-index

214800

47  
g-index

107  
all docs

107  
docs citations

107  
times ranked

4732  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Diagnosis of Leptomeningeal Metastasis in Women With Breast Cancer Through Identification of Tumor Cells in Cerebrospinal Fluid Using the CNSideâ„¢ Assay. <i>Clinical Breast Cancer</i> , 2022, 22, e457-e462.  | 2.4  | 6         |
| 2  | Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 509-516.   | 2.5  | 4         |
| 3  | Individualizing Adjuvant Therapy in Women With Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Node-Positive Breast Cancer. <i>JCO Oncology Practice</i> , 2022, , OP2100780.   | 2.9  | 1         |
| 4  | Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 195, 127-139.  | 2.5  | 15        |
| 5  | Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification. <i>Annals of Oncology</i> , 2022, 33, 702-712.  | 1.2  | 24        |
| 6  | Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with <i>PIK3CA</i> -mutated, hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 1052-1052. | 1.6  | 4         |
| 7  | Phase Ib/II study of BCL-2 inhibitor lisaftoclax (APG-2575) safety and tolerability when administered alone or combined with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in patients with estrogen receptor-positive (ER <sup>+</sup> ) breast cancer or advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS1122-TPS1122.             | 1.6  | 0         |
| 8  | Durable Clinical Activity to the AKT Inhibitor Ipatasertib in a Heavily Pretreated Patient With an AKT1 E17K Mutant Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, e150-e153.   | 2.4  | 7         |
| 9  | On the Road to Precision: Understanding the Biology Driving Genomic Assays. <i>Journal of Clinical Oncology</i> , 2021, 39, 100-102.   | 1.6  | 5         |
| 10 | Changes in Diffuse Optical Tomography Images During Early Stages of Neoadjuvant Chemotherapy Correlate with Tumor Response in Different Breast Cancer Subtypes. <i>Clinical Cancer Research</i> , 2021, 27, 1949-1957.   | 7.0  | 5         |
| 11 | Effect of Capiwasertib in Patients With an <i>AKT1 E17K</i> -Mutated Tumor. <i>JAMA Oncology</i> , 2021, 7, 271.   | 7.1  | 49        |
| 12 | Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 427-432.  | 2.5  | 12        |
| 13 | Treatment-related side effects and views about dosage assessment to sustain quality of life: Results of an advocate-led survey of patients with metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 1005-1005.  | 1.6  | 8         |
| 14 | A phase I/IIb study evaluating GDC-0077 (inavolisib) + palbociclib (palbo) + fulvestrant in patients (pts) with <i>PIK3CA</i> -mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC). <i>Senologie - Zeitschrift f r Mammadiagnostik Und -therapie</i> , 2021, 18, .  | 0.0  | 1         |
| 15 | Quantitative Multiplex Immunofluorescence Evaluation of the Tumor Microenvironment in Pretreatment Tumors of Patients with Metastatic Breast Cancer and Serous Ovarian Carcinoma Treated with Liposomal Eribulin. <i>Cancer Investigation</i> , 2021, 39, 466-472.   | 1.3  | 0         |
| 16 | When the World Throws You a Curve Ball: Lessons Learned in Breast Cancer Management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e79-e89.   | 3.8  | 3         |
| 17 | Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 177-185.   | 2.5  | 15        |
| 18 | Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy. <i>Nature Cancer</i> , 2021, 2, 658-671.  | 13.2 | 34        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Abstract 645: Network-based assessment of HDAC6 activity is highly predictive of pre-clinical and clinical responses to the HDAC6 inhibitor ricolinostat. , 2021, , .  |     | 0         |
| 20 | Diffuse optical tomography breast imaging measurements are modifiable with pre-surgical targeted and endocrine therapies among women with early stage breast cancer. Breast Cancer Research and Treatment, 2021, 189, 297-304.                 | 2.5 | 2         |
| 21 | Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2~ negative breast cancer. Breast Cancer Research and Treatment, 2021, 189, 1-13.   | 2.5 | 3         |
| 22 | Care Delivery Impact of the COVID-19 Pandemic on Breast Cancer Care. JCO Oncology Practice, 2021, 17, e1215-e1224.   | 2.9 | 36        |
| 23 | Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Annals of Oncology, 2021, 32, 1148-1156.  | 1.2 | 146       |
| 24 | Integration of germline multigene panel testing into breast and gynecologic oncology clinics.. Journal of Clinical Oncology, 2021, 39, 164-164.  | 1.6 | 0         |
| 25 | Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography. Breast Cancer Research, 2021, 23, 16.  | 5.0 | 2         |
| 26 | Advances in Therapeutic Approaches for Triple-Negative Breast Cancer. Clinical Breast Cancer, 2021, 21, 383-390.   | 2.4 | 18        |
| 27 | Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study. Frontiers in Oncology, 2021, 11, 810023.  | 2.8 | 6         |
| 28 | A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer. Clinical Breast Cancer, 2020, 20, e251-e260. | 2.4 | 15        |
| 29 | Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer. Clinical Breast Cancer, 2020, 20, 80-86.   | 2.4 | 22        |
| 30 | Association between nonadherence to cardiovascular risk factor medications after breast cancer diagnosis and incidence of cardiac events. Cancer, 2020, 126, 1541-1549.  | 4.1 | 12        |
| 31 | Prospective Study Evaluating Changes in Bone Quality in Premenopausal Women With Breast Cancer Undergoing Adjuvant Chemotherapy. Clinical Breast Cancer, 2020, 20, e327-e333.  | 2.4 | 5         |
| 32 | Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial. Annals of Oncology, 2020, 31, 1709-1718.                              | 1.2 | 86        |
| 33 | Characteristics and outcomes of patients with breast cancer diagnosed with SARS-Cov-2 infection at an academic center in New York City. Breast Cancer Research and Treatment, 2020, 182, 239-242.  | 2.5 | 43        |
| 34 | Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer. Frontiers in Oncology, 2020, 10, 968.  | 2.8 | 15        |
| 35 | Propranolol: What is BLOCKing Its Clinical Investigation in Breast Cancer?. Clinical Cancer Research, 2020, 26, 1781-1783.   | 7.0 | 3         |
| 36 | Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG). Clinical Breast Cancer, 2020, 20, 183-193.   | 2.4 | 13        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Abstract CT011: Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL. <i>Cancer Research</i> , 2020, 80, CT011-CT011.  | 0.9 | 18        |
| 38 | A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1015-1015.   | 1.6 | 28        |
| 39 | The COVID-19 pandemic impact on breast cancer care delivery at an academic center in New York City.. <i>Journal of Clinical Oncology</i> , 2020, 38, 88-88.  | 1.6 | 0         |
| 40 | Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz049.   | 2.9 | 11        |
| 41 | Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz050.   | 2.9 | 15        |
| 42 | Dynamic Vascular Optical Tomographic Imaging for Peripheral Artery Disease and Breast Cancer. , 2019, , 353-400.   |     | 4         |
| 43 | Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer. <i>Future Oncology</i> , 2019, 15, 1641-1653.   | 2.4 | 14        |
| 44 | Current Landscape of Immunotherapy in Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1205.   | 7.1 | 260       |
| 45 | Lymph node involvement: Positive about the role of the recurrence score in estrogen-driven breast cancer?. <i>Cancer</i> , 2019, 125, 177-180.   | 4.1 | 3         |
| 46 | Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors. <i>Drugs of Today</i> , 2019, 55, 575.   | 1.1 | 30        |
| 47 | Diffuse optical tomography of the breast: a potential modifiable biomarker of breast cancer risk with neoadjuvant chemotherapy. <i>Biomedical Optics Express</i> , 2019, 10, 4305.   | 2.9 | 9         |
| 48 | A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 547-557.           | 2.5 | 32        |
| 49 | Dynamic Diffuse Optical Tomography for Monitoring Neoadjuvant Chemotherapy in Patients with Breast Cancer. <i>Radiology</i> , 2018, 287, 778-786.  | 7.3 | 39        |
| 50 | Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG). <i>Breast Cancer Research and Treatment</i> , 2018, 171, 11-20. | 2.5 | 32        |
| 51 | Concurrent use of capecitabine with radiation therapy and survival in breast cancer (BC) after neoadjuvant chemotherapy. <i>Clinical and Translational Oncology</i> , 2018, 20, 1280-1288.   | 2.4 | 4         |
| 52 | Invasive Lobular Breast Carcinoma: Pleomorphic Versus Classical Subtype, Associations and Prognosis. <i>Clinical Breast Cancer</i> , 2018, 18, 114-120.  | 2.4 | 11        |
| 53 | Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 277-288.  | 2.5 | 35        |
| 54 | Expanding the Criteria for Nipple-Sparing Mastectomy in Patients With Poor Prognostic Features. <i>Clinical Breast Cancer</i> , 2018, 18, 229-233.   | 2.4 | 25        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Obesity's impact on survival is independent of dose adjustments in neoadjuvant chemotherapy in women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 285-285.  | 2.5 | 2         |
| 56 | Exceptional Response to Dacarbazine in Uterine Leiomyosarcoma With Homozygous BRCA2 Deletion Highlights the Role of Homologous Recombination in Response to DNA Damage From Alkylating Agents. <i>JCO Precision Oncology</i> , 2018, 2, 1-6.  | 3.0 | 1         |
| 57 | Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial. <i>Clinical and Translational Oncology</i> , 2018, 20, 1474-1483.   | 2.4 | 20        |
| 58 | Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2- metastatic breast cancer (mBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 1004-1004.  | 1.6 | 14        |
| 59 | Phase IB trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1058-1058.   | 1.6 | 1         |
| 60 | A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab and pertuzumab in HR-positive, Her2-positive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS1103-TPS1103.   | 1.6 | 1         |
| 61 | Association of Akt inhibition with change in immunophenotype of tumor microenvironment (TME) in breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 12057-12057.   | 1.6 | 0         |
| 62 | Proteomic modulation in breast tumors after metformin exposure: results from a "window of opportunity" trial. <i>Clinical and Translational Oncology</i> , 2017, 19, 180-188.   | 2.4 | 9         |
| 63 | Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 533-540.  | 2.5 | 15        |
| 64 | A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607). <i>Cancer</i> , 2017, 123, 2688-2697.   | 4.1 | 103       |
| 65 | Bevacizumab in breast cancer: a targeted therapy still in search of a target population. <i>Seminars in Oncology</i> , 2017, 44, 286-287.   | 2.2 | 2         |
| 66 | A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS1112-TPS1112. | 1.6 | 4         |
| 67 | Therapy for chemopretreated metastatic urothelial cancer (mUC) with the antibody-drug conjugate (ADC) sacituzumab govitecan (IMMU-132).. <i>Journal of Clinical Oncology</i> , 2017, 35, 327-327.   | 1.6 | 5         |
| 68 | Differences in global toxicity burden among patients and care providers during initial chemotherapy for breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21649-e21649.  | 1.6 | 0         |
| 69 | Concurrent use of capecitabine with radiation therapy and survival in breast cancer (BC) after neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12117-e12117.  | 1.6 | 0         |
| 70 | Characterization of the tumor immune microenvironment (TIM) with multiplex immunohistochemistry (mIHC) in patients with breast cancer following treatment with MK-2206.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12109-e12109.   | 1.6 | 0         |
| 71 | Obesity and survival in the neoadjuvant breast cancer setting: Role of tumor subtype and race.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12136-e12136.  | 1.6 | 0         |
| 72 | AKT in cancer: new molecular insights and advances in drug development. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 943-956.  | 2.4 | 209       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 555-564.   | 2.5 | 50        |
| 74 | An analysis of the relationship between metastases and cachexia in lung cancer patients. <i>Cancer Medicine</i> , 2016, 5, 2641-2648.  | 2.8 | 25        |
| 75 | Long-term Diet and Biomarker Changes after a Short-term Intervention among Hispanic Breast Cancer Survivors: The <i>¡Cocinar Para Su Salud!</i> Randomized Controlled Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1491-1502.     | 2.5 | 33        |
| 76 | Monitoring Metastasis and Cachexia in a Patient with Breast Cancer: A Case Study. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10, CMO.S40479.  | 1.3 | 22        |
| 77 | Trop-2 as a therapeutic target for the antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132), in patients (pts) with previously treated metastatic small-cell lung cancer (mSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8559-8559.     | 1.6 | 4         |
| 78 | A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and vulvovaginal melanomas: A trial of the ECOG-ACRIN Cancer Research Group (E2607).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9501-9501.    | 1.6 | 3         |
| 79 | Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.. <i>Journal of Clinical Oncology</i> , 2016, 34, LBA509-LBA509. | 1.6 | 3         |
| 80 | Lymphovascular invasion and survival in breast cancer after neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1025-1025.  | 1.6 | 0         |
| 81 | Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.. <i>Journal of Clinical Oncology</i> , 2016, 34, LBA509-LBA509. | 1.6 | 0         |
| 82 | Comparison of physicians, nurses' and patients' assessment of overall symptom burden.. <i>Journal of Clinical Oncology</i> , 2016, 34, e18123-e18123.  | 1.6 | 0         |
| 83 | Pleomorphic invasive lobular breast carcinoma: Prognosis and characteristics compared with classical invasive lobular breast carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, e13094-e13094.  | 1.6 | 0         |
| 84 | Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy. <i>SpringerPlus</i> , 2015, 4, 386.  | 1.2 | 27        |
| 85 | Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ. <i>Breast Journal</i> , 2015, 21, 377-386.  | 1.0 | 34        |
| 86 | Identifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics Technology. <i>PLoS ONE</i> , 2015, 10, e0145816.  | 2.5 | 28        |
| 87 | ¡Cocinar Para Su Salud!: Randomized Controlled Trial of a Culturally Based Dietary Intervention among Hispanic Breast Cancer Survivors. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2015, 115, 709-723.e3.                                    | 0.8 | 51        |
| 88 | ¡Cocinar Para Su Salud!: Randomized Controlled Trial of a Culturally Based Dietary Intervention among Hispanic Breast Cancer Survivors. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2015, 115, S42-S56.e3.                                    | 0.8 | 27        |
| 89 | Inhibition of the autocrine IL-6“JAK2“STAT3“calprotectin axis as targeted therapy for HR<sup>+</sup>/HER2<sup>+</sup> breast cancers. <i>Genes and Development</i> , 2015, 29, 1631-1648.  | 5.9 | 94        |
| 90 | Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients. <i>Clinical and Translational Oncology</i> , 2015, 17, 539-546.   | 2.4 | 45        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | A phase Ib study of abemaciclib with therapies for metastatic breast cancer.. Journal of Clinical Oncology, 2015, 33, 522-522.   | 1.6 | 13        |
| 92  | Safety, Feasibility, and Biomarker Effects of High-Dose Vitamin D Supplementation Among Women at High Risk for Breast Cancer. International Journal of Food Science, Nutrition and Dietetics, 2015, 2015, 1-9.                         | 0.0 | 13        |
| 93  | Identifying predictors of taxane-induced peripheral neuropathy using shotgun proteomics technology.. Journal of Clinical Oncology, 2015, 33, 9607-9607.  | 1.6 | 0         |
| 94  | Randomized sham controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy.. Journal of Clinical Oncology, 2015, 33, e20738-e20738.   | 1.6 | 0         |
| 95  | Presurgical Trial of Metformin in Overweight and Obese Patients with Newly Diagnosed Breast Cancer. Cancer Investigation, 2014, 32, 150-157.   | 1.3 | 66        |
| 96  | Increased Expression of Tumor Proliferation Genes in Hispanic Women with Early-Stage Breast Cancer. Cancer Investigation, 2014, 32, 439-444.   | 1.3 | 14        |
| 97  | Presurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer.. Journal of Clinical Oncology, 2014, 32, 2613-2613.  | 1.6 | 3         |
| 98  | Correlation between risk benefit index and uptake of breast cancer chemoprevention.. Journal of Clinical Oncology, 2014, 32, 1568-1568.  | 1.6 | 0         |
| 99  | Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2-positive breast cancer.. Journal of Clinical Oncology, 2014, 32, TPS666-TPS666.   | 1.6 | 0         |
| 100 | Phase III study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer.. Journal of Clinical Oncology, 2014, 32, 598-598.                | 1.6 | 1         |
| 101 | Ethnic differences in tumor proliferation in women with early-stage breast cancer.. Journal of Clinical Oncology, 2013, 31, 560-560.   | 1.6 | 0         |
| 102 | Cracking Open Window of Opportunity Trials. Journal of Clinical Oncology, 2012, 30, 2573-2575.   | 1.6 | 36        |
| 103 | Mutational analysis of circulating tumor cells in breast cancer patients by targeted clonal sequencing.. Journal of Clinical Oncology, 2012, 30, 10516-10516.  | 1.6 | 1         |
| 104 | Immunocytochemistry staining for ER and PR in circulating tumor cells as compared to primary tumor or metastatic biopsy.. Journal of Clinical Oncology, 2012, 30, 584-584.   | 1.6 | 5         |
| 105 | A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas: An Eastern Cooperative Oncology Group study (E2607).. Journal of Clinical Oncology, 2012, 30, 8522-8522. | 1.6 | 2         |
| 106 | PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression. Breast Cancer Research and Treatment, 2011, 129, 635-643.  | 2.5 | 49        |
| 107 | PIK3CA Mutation Associates with Improved Outcome in Breast Cancer. Clinical Cancer Research, 2009, 15, 5049-5059.  | 7.0 | 338       |